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ABSTRACT
Adult pleomorphic rhabdomyosarcoma (RMS) is a rare and recalcitrant, highly-
malignant mesenchymal tumor in need of improved therapeutic strategies. Our 
laboratory pioneered the patient-derived orthotopic xenograft (PDOX) nude mouse 
model with the technique of surgical orthotopic implantation (SOI). We previously 
described the development of a PDOX model of adult pleomorphic RMS where the tumor 
behaved similar to the patient donor. A high-grade pleomorphic rhabdomyosarcoma 
from a striated muscle was previously grown orthotopically in the right biceps-femoris 
muscle of nude mice to establish the PDOX model. In the present study, the PDOX 
models were randomized into the following treatment groups when tumor volume 
reached 100 mm3: G1, control without treatment; G2, cyclophosphamide (CPA) 140 
mg/kg, intraperitoneal (i.p.) injection, weekly, for 3 weeks; G3, temozolomide (TEM), 
25 mg/kg, per oral (p.o.), daily, for 21 days; G4, temozolomide (TEM) 25 mg/kg, p.o., 
daily, for 21 days combined with irinotecan (IRN), 4 mg/kg, i.p., daily for 21 days. 
After 3 weeks, treatment of PDOX with TEM combined with IRN was so powerful that 
it resulted in tumor regression and the smallest tumor volume compared to other 
groups. The RMS PDOX model should be of use to design the treatment program for 
the patient and for drug discovery and evaluation for this recalcitrant tumor type.
INTRODUCTION
Rhabdomyosarcoma (RMS) originates in striated 
muscle cells. The majority of RMS cases occur below 
the age of 18. Approximately 40% of soft tissue sarcomas 
(STS) are RMS. RMS can occur in any site on the body but 
is primarily found in the head, neck, orbit, genitourinary 
tract, genitals, and extremities [1–3]. RMS is divided into 
three histological subsets:
Embryonal rhabdomyosarcoma (ERMS) is the most 
common with approximately 60-70% of childhood cases. 
ERMS usually occurs in patients 4 years old or younger 
with 4 cases per 1 million children. Head and neck as well 
as the genitourinary track are most common sites. ERMS 
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usually has morphology similar to developing muscle cells 
of a 6-8 week-old embryo, hence the name. ERMS also 
has two subtypes, botryoid and spindle cell [4, 5].
Alveolar rhabdomyosarcoma (ARMS) has an 
incidence of 1 case per 1 million in patients aged 0 to 19. 
ARMS occurs most commonly in extremities, trunk, and 
peritoneum and is more aggressive than ERMS. ARMS is 
the most common form of RMS observed in young adults 
and teenagers. ARMS has densely-packed, round cells that 
are similar to pulmonary alveoli, hence the name [5, 6].
Pleiomorphic rhabdomyhosarcoma (PRMS) 
comprises poorly differentiated anaplastic cells. PRMS is 
the most aggressive type of RMS [7]. PRMS occurs most 
often in adults and rarely in children. RMS is usually in 
the extremities [8, 9].
We previously developed a patient-derived orthotopic 
xenograft (PDOX) mouse model of PRMS. We compared 
the PDOX model to a subcutaneous (s.c.)-transplant model. 
An RMS from a striated muscle of a male patient was 
grown orthotopically in the right biceps- femoris muscle or 
right quadriceps muscle of nude mice to establish a PDOX 
model. The RMS was also grown subcutaneously in nude 
mice. PDOX tumors grew at a statistically-significant faster 
rate compared to the s.c. tumors. Recurrence after surgical 
resection occurred only in PDOX tumors, not in the s.c. 
model. Histologically, only the PDOX model was shown to be 
invasive. These results indicated that the PDOX model of adult 
RMS is malignant and the subcutaneous model is benign [10].
In the present study, we used the adult PRMS PDOX 
model to identify an effective drug or combination for this 
recalcitrant disease.
RESULTS AND DISCUSSION
Efficacy of cyclophosphamide (CPA), 
temozolomide (TEM) and TEM combined with 
irinotecan (IRN) on the PRMS PDOX
Please see Figure 1 for treatment schema. All 
treatments significantly inhibited the PRMS PDOX growth 
compared to untreated controls on day 21 after initiation. 
Tumor volumes at day 21 were: control (G1): 640.6 ± 
225.5 mm3; CPA (G2): 301.1 ± 43.6 mm3, p=0.002; TEM 
(G3): 215.2 ± 40.6 mm3, p=0.0004; TEM combined with 
IRN (G4): 93.6 ± 8.7 mm3, p<0.0001. TEM combined 
with IRN showed significantly more efficacy compared 
to other therapies evaluated: CPA (p<0.0001), TEM 
(p=0.0002) (Figures 2 and 3). There were no animal 
Figure 1: Treatment schema.
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Figure 2: Efficacy of cyclophosphamide (CPA), temozolomide (TEM) and TEM combined with irinotecan (IRN). CPA 
(140 mg/kg, i.p., qw×3); TEM (25 mg/kg, p.o., qd×21); TEM (25 mg/kg, p.o., qd×21) combined with IRN (4 mg/kg, i.p., qd×21). Tumor 
volume was measured at the indicated time points after the onset of treatment. Please see the Materials and Methods for details. N = 8 mice/
group. *P=0.0002; **P<0.0001.
Figure 3: Efficacy of CPA, TEM and TEM combined with IRN. Photographs of representative PDOX mouse models from each 
treatment group at day 21.
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deaths in any group. The body weight of treated mice was 
not significantly different in any group (Figure 4). No 
significant other side effects were observed either.
Histology of the PRMS PDOX and patient tumor
A high-power photomicrograph of the original 
patient tumor displayed solid sheets of tumor cells 
characterized by pleomorphic, hyperchromatic, enlarged 
nuclei with coarse chromatin and moderate amounts of 
lightly eosinophilic cytoplasm. Numerous mitotic figures, 
including atypical forms are present. A high-power image 
of the orthotopically-implanted tumors had very similar 
features, including pleomorphic, hyperchromatic, enlarged 
nuclei with coarse chromatin and moderate amounts of 
lightly eosinophilic cytoplasm. Numerous mitotic figures, 
including atypical forms are also present (Figure 5), 
demonstrating the fidelity of the PDOX tumor.
The donor patient was newly diagnosed with PRMS 
which is considered a high-grade sarcoma. The patient 
had not received any prior systemic treatment. There 
is no consensus as to what the standard of care therapy 
is for this disease [11–13]. Therefore, it was decided to 
choose some systemic therapies that are used for RMS 
such as IRN and CPA. It was decided to try IRN + TMZ 
since this is a combination regimen that has been used 
for various malignancies and has shown efficacy against 
a wide range of tumors and several forms of sarcoma. 
Figure 4: Effect of treatment on body weight. Bar graph shows body weight in each group at pre-treatment and 3 weeks after drug 
administration.
Figure 5: Histology of the original patient tumor and the untreated control PDOX tumor. (A) Original patient 
tumor. (B) Untreated control PDOX tumor. See Materials and Methods for details.
Oncotarget75878www.impactjournals.com/oncotarget
Although this combination is not commonly used for 
PRMS, our unexpected results show tumor regression 
with this combination. This promising result makes the 
combination of TEM and IRN a candidate therapy for the 
donor patient of the PRMS PDOX, since tumor regression 
in the model suggested efficacy in the clinic [14]. A future 
study will determine if the combination of TEM and IRN 
is synergistic or additive in this model of PRMS.
Previously-developed concepts and strategies of 
highly selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [15–20].
CONCLUSIONS
RMS is a recalcitrant disease. It usually occurs in 
children and young adults. In the present case, it occurred in 
68-year-old man. We previously established a PDOX model 
of pleomorphic RMS (PRMS) [10] that is highly malignant 
compared to the same tumor grown subcutaneously. 
Therefore, we assume the PDOX model represents the 
patient since PRMS is a highly-malignant tumor. The 
present results show that the combination of TEM and IRN 
was so powerful that it was able to regress the RMS PDOX, 
indicating potential of a similar response in the patient [14].
The combination of vincristine, actinomycin D, 
cyclophosphamide (VAC) is sometimes used to treat RMS 
and will be used for future experiments comparing VAC 
with TEM+IRN [21]. The results of the present study 
suggests that potential powerful therapy can be identified 
for many adult PRMS patients. The PRMS PDOX can be 
used for discovery and evaluation of novel therapeutics for 
this recalcitrant disease as well.
MATERIALS AND METHODS
Animal care
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. Animals 
were housed in a barrier facility on a high efficiency 
particulate arrestance (HEPA)-filtered rack under standard 
conditions of 12-hour light/dark cycles. The animals were 
fed an autoclaved laboratory rodent diet. All animal studies 
were conducted with an AntiCancer Institutional Animal 
Care and Use Committee (IACUC)-protocol specifically 
approved for this study and in accordance with the principals 
and procedures outlined in the National Institute of Health 
Guide for the Care and Use of Animals under Assurance 
Number A3873-1. In order to minimize any suffering of the 
animals, anesthesia and analgesics were used for all surgical 
experiments. Animals were anesthetized by subcutaneous 
injection of a 0.02 ml solution of 20 mg/kg ketamine, 15.2 
mg/kg xylazine, and 0.48 mg/kg acepromazine maleate.
Patient-derived tumor
A 68-year-old male diagnosed with pleomorphic 
RMS had a large primary tumor in the right high thigh 
previously underwent surgical resection at Department 
of Surgery, University of California, Los Angeles 
(UCLA). The patient did not receive any chemotherapy 
or radiotherapy prior to surgery. Written informed 
consent was obtained from the patient as part of a UCLA 
Institutional Review Board (IRB #10-001857)-approved 
protocol [10].
Surgical orthotopic implantation (SOI) to 
establish an RMS PDOX model
Our laboratory pioneered the PDOX nude 
mouse model with the technique of surgical orthotopic 
implantation (SOI), including pancreatic [22–25], breast 
[26], ovarian [27], lung [28], cervical [29], colon [30–
32], stomach [33], sarcoma [34–38], and melanoma 
[39–41].
The PRMS tumor was previously established at 
AntiCancer, Inc. [10]. Tumors were initially grown 
subcutaneously after transplantation of 5 mm fragments. 
After 3 weeks growth, tumors were harvested and cut 
into small fragments (3-4 mm). After nude mice were 
anesthetized, a 5 mm skin incision was made on the right 
high thigh, then the biceps femoris or quadriceps was split 
to make space for the tumor. A single tumor fragment 
was implanted orthotopically into the space to establish a 
PDOX model [10]. The wound was closed with 6-0 nylon 
suture (Ethilon, Ethicon, Inc., NJ, USA).
Treatment design
PRMS PDOX mouse models were randomized into 
4 groups of 8 mice each: G1, control without treatment; 
G2, CPA 140 mg/kg, i.p., qw×3; G3, TEM 25 mg/kg, p.o., 
qd×21; G4, TEM 25 mg/kg, p.o., qd×21 combined with 
IRN 4 mg/kg, i.p., qd×21. Tumor length, width and mouse 
body weight were measured twice in a week. Tumor 
volume was calculated by following formula: Tumor 
volume (mm3) = length (mm) × width (mm) × width (mm) 
× 1/2. Data are presented as mean ± SD. 
Histological analysis
Fresh tumor specimens were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (3 μm) were deparaffinized in xylene and 
rehydrated in an ethanol series. Hematoxylin and eosin 
(H&E) staining was performed according to standard 
protocol. Histological examination was performed with 
a BHS system microscope. Images were acquired with 
INFINITY ANALYZE software (Lumenera Corporation, 
Ottawa, Canada).
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